Kandler, Kristian

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,128

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 868

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 124

Once-Weekly Semaglutide 7·2 Mg in Adults with Obesity (STEP UP): A Randomised, Controlled, Phase 3b Trial

Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 119

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

Verma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023) · eClinicalMedicine

Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

Cited by 106

Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials

Heerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 98

1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial

WHARTON, S., FREITAS, P., HJELMESÆTH, J., KABISCH, M., KANDLER, K., LINGVAY, I., DE LOS ANGELES QUIROGA, M., ROSENSTOCK, J., & GARVEY, W. T. (. (2025) · Diabetes

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 8